Advanced Molecular Nuclear Imaging Market By Product Type (SPECT Systems, Hybrid PET Systems, Planar Scintigraphy), By Application ( Oncology, Cardiology, and Other Applications), By End-User (Hospitals, Imaging Centers, Academic and Research Centers) and by Region and Companies Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2022-2032.

Advanced Molecular Nuclear Imaging Market Overview:

The Advanced Molecular Nuclear Imaging Market is projected to reach a valuation of USD 7,604.81 Mn by 2032 at a CAGR of 5.3%, from USD 4,309 Mn in 2021.

Advanced molecular nuclear imaging techniques are a form of non-invasive, painless medical tests that aid doctors in diagnosing and examining medical disorders. Radiopharmaceutical or radiotracer compounds are used in these imaging tests.

Molecular imaging is a sort of medical imaging that creates precise images of what’s going on inside the body at a molecular and cellular level. Molecular imaging, unlike other diagnostic imaging technologies such as X-rays, Computed Tomography (CT), and ultrasound, allows clinicians to view how the body is functioning, and measure its chemical and biological processes.

Nuclear medicine, which uses very small amounts of radioactive materials (radiopharmaceuticals) to diagnose and cure disease, falls under the category of molecular imaging. In nuclear medicine imaging, radiopharmaceuticals are detected by special sorts of cameras that operate with computers to generate very precise images of an area of the body that is being examined.

Certain types of cancer and another type of disorders can also be diagnosed with nuclear medicine.

Molecular imaging provides clinicians with unique insights into the human body, allowing them to tailor patient therapy.

Detailed Segmentation

Product Type:

• SPECT Systems
• Hybrid PET Systems
• Planar Scintigraphy

Application:

• Oncology
• Cardiology
• Neurology
• Other Applications

End-User:

• Hospitals
• Imaging Centers
• Academic and Research Centers

Based on Region:

• North America
• Europe
• Asia-Pacific
• South America
• Middle East & Africa

Market Dynamics

Drivers for the Global Advanced Molecular Nuclear Imaging Market:

Increasing investments toward diagnostic imaging center innovation, as well as the development of new radiotracers, are key factors augmenting this market’s economic growth. An increase in the prevalence and incidence of cancer and cardiovascular diseases, as well as high nuclear imaging accuracy, are other major factors fueling the progression of the advanced molecular nuclear imaging market.

Restraints Global Advanced Molecular Nuclear Imaging Market:

High product costs and several stringent regulations, among other factors, are expected to restrain the economic growth of the advanced molecular nuclear imaging market over the forecast period.

Opportunities for the Global Advanced Molecular Nuclear Imaging Market:

An increase in research & development activities, as well as a surge in the demand from emerging nations, are anticipated to create additional opportunities for players operating in the advanced molecular nuclear imaging market.

Trends for the Global Advanced Molecular Nuclear Imaging Market:

Nuclear medicine has significant potential to treat cancer and heart disease. There is substantial evidence that using nuclear imaging techniques to diagnose a tumor has a greater impact on patient management in terms of tumor surveillance and treatment response.

Competitive Landscape

• Cardinal Health
• Jubilant Pharma Holdings Inc.
• Novartis AG
• Siemens Healthcare GmbH
• Koninklijke Philips N.V.
• General Electric Company
• Neusoft Corporation
• Mediso Ltd.
• CMR Naviscan Corporation
• SurgicEye GmbH